Human papillomavirus (HPV) infects large numbers of women worldwide and is present in more than 99% of all cervical cancer. TC-1 cell is a cell line with high expression of E7 antigen of HPV type 16 and its cell lysate has been demonstrated as an ideal inducer of E7-specific, antitumor immunity. OK-432 (Picibanil), a penicillin-killed Streptococcus pyogenes, has been reported with potent immunomodulation properties in cancer treatment by stimulating the maturation of dendritic cells (DCs) and secretion of Th-1 type cytokines. The current study demonstrated that a protocol to immunize the C57BL/6 mice with OK-432 followed by treatment with TC-1 lysate can generate markedly increased immune responses of E7-specific CD4+ T cells and a moderate increase of natural killer (NK) cell, as well as a satisfactorily protective and therapeutic antitumor effect by triggering the DCs to prime T cells. Depletion of lymphocyte subset in vivo suggested that the antitumor effects could be dominantly executed by CD8+ T cells and followed by NK cells, and both of these reactions were induced by the generation of robust E7-specific CD4+ T helper cell response. These findings warrant OK-432 combination with tumor-lysate as an effective and safe vaccine in future clinical application of cervical cancer.
WalboomersJMJacobsMVManosMM. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–19.
2.
ParkinDMBrayFFerlayJPisaniP. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108.
3.
ItohTUedaYOkugawaK. Streptococcal preparation OK432 promotes functional maturation of human monocyte-derived dendritic cells. Cancer Immunol Immunother. 2003; 52(4):207–214.
4.
OnoTKurataSWakabayashiKSugawaraYSaitoM. Inhibitory effect of a streptococcal preparation (OK-432) on the nucleic acid synthesis in tumor cells in vitro. Gann Gan. 1973;64(1):59–64.
5.
OshimiKKanoSTakakuFOkumuraK. Augmentation of mouse natural killer cell activity by a streptococcal preparation, OK-432. J Nation Cancer Ins. 1980;65(6):1265–1269.
6.
SaitoMNanjoMKataokaM. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. Cancer Res. 1988;48(15):4163–4167.
7.
SaitoMNanjoMAonumaE. Activated macrophages are responsible for the tumor-inhibitory effect in mice receiving intravenous injection of OK-432. Int J Cancer. 1984;33(2):271–276.
8.
ShitaraKIchimuraOMitsunoTOsawaT. Natural killer (NK) cell activating factor released from murine thymocytes stimulated with an anti-tumor streptococcal preparation, OK-432. J Immunol. 1985;134(2):1039–1047.
9.
WakasugiHKasaharaTMinatoNHamuroJMiyataMMoriokaY. In vitro potentiation of human natural killer cell activity by a streptococcal preparation, OK-432: interferon and interleukin-2 participation in the stimulation with OK-432. J Nation Cancer Ins. 1982;69(4):807–812.
10.
KitsukiHKatanoMIkuboA. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clinical Immunol Immunopathol. 1996;78(3):283–290.
11.
OkamotoTHaradaMTamadaK. Local injection of OK432 can augment the TH1-type T-cell response in tumor-draining lymph node cells and increase their immunotherapeutical potential. Int J Cancer. 1997;70(5):598–605.
12.
RyomaYMoriyaYOkamotoMKanayaISaitoMSatoM. Biological effect of OK-432 (picibanil) and possible application to dendritic cell therapy. Anticancer Res. 2004;24(5C):3295–3301.
13.
MittendorfEAHolmesJPPonniahSPeoplesGE. The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother. 2008;57(10):1511–1521.
14.
LinCTTsaiYCHeL. DNA vaccines encoding IL-2 linked to HPV-16 E7 antigen generate enhanced E7-specific CTL responses and antitumor activity. Immunol Lett. 2007;114(2):86–93.
15.
zur HausenH. Papillomaviruses and cancer: from basic studies to clinical application. Nature Rev. 2002;2(5):342–350.
16.
LinCTHungCFJuangJ. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol Ther. 2003;8(4):559–566.
17.
WuAZengQKangTH. Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer. Gene Ther. October2010. Epub ahead of print.
18.
LinCTYenTCChangTC. Role of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in re-recurrent cervical cancer. Int J Gynecol Cancer. 2006;16(6):1994–2003.
19.
RosenbergSAYangJCSchwartzentruberDJ. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Med. 1998;4(3):321–327.
20.
HohnHPilchHGunzelS. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol. 1999;163(10):5715–5722.
21.
HeardISchmitzVCostagliolaDOrthGKazatchkineMD. Early regression of cervical lesions in HIV-seropositive women receiving highly active antiretroviral therapy. AIDS (London, England). 1998;12(12):1459–1464.
22.
JanssenEMLemmensEEWolfeTChristenUvon HerrathMGSchoenbergerSP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421(6925):852–856.
23.
ShedlockDJShenH. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (New York, NY. ). 2003;300(5617):337–339.
24.
SunJCBevanMJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (New York, NY). 2003;300(5617):339–342.
25.
van de BergPJvan LeeuwenEMten BergeIJvan LierR. Cytotoxic human CD4(+) T cells. Curr Opin Immunol. 2008;20(3):339–343.
26.
OkamotoMOhEGOshikawaT. Toll-like receptor 4 mediates the antitumor host response induced by a 55-kilodalton protein isolated from Aeginetia indica L., a parasitic plant. Clin Diagnos lab Immunol. 2004;11(3):483–495.
27.
KoidoSHaraEHommaS. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol. 2007;178(1):613–622.
28.
MashinoKSadanagaNTanakaFOhtaMYamaguchiHMoriM. Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. Mol Cancer Therap. 2002;1(10):785–794.
29.
SchultzESChapiroJLurquinC. The production of a new MAGE-3 peptide presented to cytolytic T lymphocytes by HLA-B40 requires the immunoproteasome. J Exp Med. 2002;195(4):391–399.
30.
RobinsonDSO'GarraA. Further checkpoints in Th1 development. Immunity. 2002;16(6):755–758.
31.
KurosawaSHaradaMShinomiyaYTeraoHNomotoK. The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells. Cancer Immunol Immunother. 1996;43(1):31–38.
32.
ZamaiLPontiCMirandolaPGobbiGPapaSGaleottiL. NK cells and cancer. J Immunol. 2007;178(7):4011–4016.
33.
KobayashiMFitzLRyanM. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989;170(3):827–845.
34.
OkamotoMKajiRKasetaniH. Purification and characterization of interferon-gamma-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-gamma-inducing activity of OK-432. J Immunother Emphasis Tumor Immunol. 1993;13(4):232–242.
